文献速递前列腺增生与排尿功能障碍

男性下尿路症状与良性前列腺增生中12个月安慰剂效应对下尿路症状及最大尿流率影响的Meta分析

A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-analysis.
PubMed 文献 · Urology · 2017-05-12

12个月时国际前列腺症状评分平均改善4.4分(范围0.7-6.8分),最大尿流率平均改善仅+0.8 mL/s,但各试验间差异显著。结论认为中期安慰剂效应主要体现在主观症状改善,且不同研究间变异较大。

要点

  • 12个月时安慰剂或假手术使IPSS平均改善4.4分(范围0.7-6.8分)。
  • 最大尿流率平均改善+0.8 mL/s,但各试验间差异显著。
  • 安慰剂效应在12个月时仍存在,以主观症状改善为主。

核心结论

  • 本Meta分析显示中期安慰剂效应对下尿路功能有影响,尤其体现在主观改善方面,且即使到12个月各研究间安慰剂效应程度仍差异较大。

研究设计与样本

  • 纳入所有适应证为良性前列腺增生和下尿路症状、含安慰剂或假手术组且随访12个月的随机对照试验。

主要发现

  • 12个月时,安慰剂或假手术治疗使国际前列腺症状评分平均改善4.4分,范围为0.7-6.8分。
  • 12个月时各干预类型下IPSS平均变化:植物提取物-3.6分、5α还原酶抑制剂-3.4分、α受体阻滞剂-4.3分、联合治疗-4.3分、A型肉毒毒素-3.9分、经尿道微波热疗-6.8分。
  • 12个月时安慰剂或假手术下最大尿流率平均改善+0.8 mL/s,但试验间差异显著:植物提取物-0.3 mL/s、5α还原酶抑制剂+0.8 mL/s、α受体阻滞剂+1.1 mL/s、联合治疗+1.4 mL/s、经尿道微波热疗+1.0 mL/s。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the mid- to long-term placebo effect of the medical and instrumental management of male lower urinary tract symptoms. This is generally a long-term treatment strategy. Therefore, knowledge on the mid- to long-term placebo effect is of considerable interest. The paucity of data on this topic prompted us to investigate this issue in a meta-analysis. METHODS: All randomized controlled trials (RCTs) with the indication of benign prostatic hyperplasia and lower urinary tract symptoms containing a placebo- or sham treatment arm and with a follow-up of 12 months were eligible. The 12-month effect of placebo or sham treatment on the International Prostate Symptom Score (the quality-of-life question was not analyzed herein) and the American Urological Association Symptom Score and on the maximum flow rate was quantified. RESULTS: A total of 25 RCTs with 10.587 patients were eligible. Twenty-three studies were placebo controlled (plant extracts: n = 4, 5α-reductase inhibitors [5ARIs]: n = 9, α-blocker: n = 5, combination therapy of 5ARI and α-blocker: n = 3, and intraprostatic botulinum toxin A injection: n = 2), and 2 RCTs with transurethral microwave thermotherapy (TUMT) had a sham treatment arm. At 12 months, the mean International Prostate Symptom Score improved by a mean of 4.4 points under placebo or sham treatment with a range of 0.7-6.8 points: plant extracts, -3.6; 5ARI, -3.4; α-blocker, -4.3; combination therapy, -4.3; botulinum toxin A, -3.9; and TUMT, -6.8. The mean maximum flow rate improvement at 12 months under placebo or sham was not relevant (+0.8 mL/s), yet there were remarkable differences between trials: plant extracts, -0.3 mL/s; 5ARI, +0.8 mL/s; α-blocker, +1.1 mL/s; combination therapy, +1.4 mL/s; and TUMT, +1.0 mL/s. CONCLUSION: This meta-analysis demonstrates the mid-term placebo effect on lower urinary tract function, particularly concerning subjective improvement. The degree of the placebo effect varies considerable between studies even at 12 months.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Eredics K, Madersbacher S, Schauer I, et al. A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-analysis. Urology. 2017. PMID: 28506862. doi:10.1016/j.urology.2017.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。